Paper published in a journal (Scientific congresses and symposiums)
Expected medium and long term impact of the COVID-19 outbreak in oncology
JERUSALEM, Guy; ONESTI, Concetta Elisa; Generali, Daniele et al.
2020In Annals of Oncology
Peer Reviewed verified by ORBi


Full Text
ESMO 2020 Jerusalem.pdf
Publisher postprint (80.46 kB)

All documents in ORBi are protected by a user license.

Send to


Abstract :
[en] Background: The ongoing SARS-CoV-2 pandemic and ensuing coronavirus disease (COVID-19) is challenging cancer care and services worldwide. Methods: A 95 items survey was distributed worldwide by 20 oncologists from 10 of the most affected countries in order to evaluate the impact on organization of oncological care. Results: 109 representatives from oncology centers in 18 countries (62.4% academic hospitals) filled out the survey (June 17 e July 14, 2020). A swab or gargle test is systematically performed before day care unit or overnight stay admissions in 27.5% and 58.7% of the centers, respectively. A local registry (64.2%) and systematic tracing (77.1%) of infected patients was organized in many centers. Treatment modalities mostly affected by the pandemic (cancellation/delay) were surgery (44.1%) and chemotherapy (25.7%). Earlier cessation of palliative treatment was observed in 32.1% of centers, and 64.2 % of participants agree that under-treatment is a major concern. At the pandemic peak, teleconsultations were performed for follow-up (94.5%), for oral therapy (92.7%), but also for patients receiving immunotherapy (57.8%) or chemotherapy (55%). Approximately 82% of participants estimate that they will continue to use telemedicine. Most participants reported more frequent use of virtual tumor boards (82%) and oncological team meetings (92%), but 45% disagree that virtual meetings are an acceptable alternative to live international meetings. Although 60.9% report reduced clinical activity during the pandemic peak, only 28.4% had an increased scientific activity. Only 18% of participants estimate that their wellbeing will not recover to previous levels by the end of the year; 63% indicate easily accessible psychological support for caregivers, but only 10% used or planned to use it. All clinical trial activities are or will soon be reactivated in 72.5% of the centers. Major study protocol violations/deviations were observed in 27.5% and significant reductions of clinical trial activities are expected by 37% of centers this year. Conclusions: COVID-19 has a major impact on organization of patient care, well-being of caregivers, continued medical education and clinical trial activities in oncology.
Disciplines :
Author, co-author :
JERUSALEM, Guy  ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
ONESTI, Concetta Elisa ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
Generali, Daniele
Harbeck, Nadia
Wildiers, Hans
Curigliano, Giuseppe
Campone, Mario
Tjan-Heijnen, Vivianne
Martin, Miguel
Cristofanilli, Massimo
Pusztai, Lajos
Bartsch, Rupert
Peeters, Marc
Berchem, Guy
Tagliamento, Marco
Cortès, Javier
Ruhsthaller, Thomas
Ciruelos, Eva
Rottey, Sylvie
Rugo, Hope
More authors (10 more) Less
Language :
Title :
Expected medium and long term impact of the COVID-19 outbreak in oncology
Publication date :
19 September 2020
Event name :
ESMO 2020 Virtual Congress
Event date :
from 19-09-2020 to 21-09-2020
Audience :
Journal title :
Annals of Oncology
Publisher :
Oxford University Press, United Kingdom
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 06 December 2020


Number of views
88 (10 by ULiège)
Number of downloads
76 (8 by ULiège)


Similar publications

Contact ORBi